Progyny (NASDAQ:PGNY) Issues FY 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.980-2.09 for the period, compared to the consensus estimate of 1.740. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q2 2026 guidance to 0.500-0.53 EPS.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on PGNY shares. BTIG Research lowered their price objective on Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Citigroup upgraded Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. Jefferies Financial Group reissued a “buy” rating and set a $30.00 price objective on shares of Progyny in a research report on Friday, March 6th. Finally, Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.91.

Progyny Trading Up 23.8%

PGNY opened at $23.72 on Friday. The stock’s 50-day moving average price is $17.87 and its 200 day moving average price is $21.69. Progyny has a 12-month low of $16.10 and a 12-month high of $28.75. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 1.10 and a beta of 0.91.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The company had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 12.76%. The business’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, research analysts forecast that Progyny will post 1.12 earnings per share for the current year.

Insider Transactions at Progyny

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the transaction, the executive vice president owned 89,879 shares of the company’s stock, valued at $1,563,894.60. This trade represents a 4.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders have sold 7,455 shares of company stock worth $129,515. 9.90% of the stock is owned by corporate insiders.

Progyny News Summary

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny beat Q1 estimates, reporting $0.50 adjusted EPS versus $0.44 expected and revenue of $328.5 million versus $326.5 million forecast, helping reinforce the stock’s move higher. Progyny, Inc. Announces First Quarter 2026 Results
• Positive Sentiment: The company raised second-quarter and full-year 2026 guidance, with Q2 EPS outlook of $0.50 to $0.53 and FY2026 EPS guidance of $1.98 to $2.09, both above Wall Street estimates, which supports confidence in future earnings power. Conference call and earnings materials
• Positive Sentiment: Management said early selling-season activity and member engagement were strong, and the company highlighted continued share repurchases, with 8.8 million shares bought back since November, adding another supportive signal for investors. Progyny, Inc. Announces First Quarter 2026 Results
• Neutral Sentiment: Revenue was still down 26.4% year over year, so while the quarter beat expectations, investors may remain focused on whether growth can stabilize after the recent decline. Progyny: Q1 Earnings Snapshot
• Neutral Sentiment: Some commentary noted concern around flat revenue guidance, which could temper the bullish reaction if investors want clearer top-line acceleration going forward. The Bull Case For Progyny (PGNY) Could Change Following Flat Q1 2026 Revenue Guidance Concerns

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in Progyny during the 4th quarter worth about $25,000. Canada Pension Plan Investment Board purchased a new position in shares of Progyny in the 2nd quarter valued at about $77,000. Quarry LP boosted its stake in shares of Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after buying an additional 3,427 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Progyny by 203.5% during the second quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock worth $154,000 after buying an additional 4,708 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of Progyny during the fourth quarter worth approximately $203,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.